Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Mohan Raju | CEO AND PRESIDENT | Jun 10 '24 | Option Exercise | 0.20 | 96,778 | 19,356 | 1,675,028 | Jun 11 04:47 PM | Mohan Raju | CEO AND PRESIDENT | Apr 02 '24 | Sale | 5.40 | 4,312 | 23,299 | 1,578,250 | Apr 03 07:32 PM | Krueger Christopher W | CHIEF BUSINESS OFFICER | Apr 02 '24 | Sale | 5.40 | 1,651 | 8,921 | 284,999 | Apr 03 07:37 PM | Nuss John | CHIEF SCIENTIFIC OFFICER | Apr 02 '24 | Sale | 5.40 | 1,651 | 8,921 | 264,998 | Apr 03 07:33 PM | Auster Martin | CHIEF FINANCIAL OFFICER | Apr 02 '24 | Sale | 5.40 | 1,405 | 7,592 | 24,303 | Apr 03 07:30 PM | Krueger Christopher W | CHIEF BUSINESS OFFICER | Mar 28 '24 | Option Exercise | 0.00 | 4,531 | 0 | 286,650 | Mar 29 06:15 PM | Auster Martin | CHIEF FINANCIAL OFFICER | Mar 28 '24 | Option Exercise | 0.00 | 4,531 | 0 | 25,708 | Mar 29 06:12 PM | Mohan Raju | CEO AND PRESIDENT | Mar 28 '24 | Option Exercise | 0.00 | 11,843 | 0 | 1,582,562 | Mar 29 06:09 PM | Nuss John | CHIEF SCIENTIFIC OFFICER | Mar 28 '24 | Option Exercise | 0.00 | 4,531 | 0 | 266,649 | Mar 29 06:07 PM | Mohan Raju | CEO and President | Dec 20 '23 | Sale | 2.12 | 58,860 | 124,660 | 1,570,719 | Dec 21 08:10 PM | Nuss John | Chief Scientific Officer | Dec 20 '23 | Sale | 2.12 | 17,628 | 37,334 | 262,118 | Dec 21 08:14 PM | Krueger Christopher W | Chief Business Officer | Dec 20 '23 | Sale | 2.12 | 5,293 | 11,210 | 282,119 | Dec 21 08:12 PM | Krueger Christopher W | Chief Business Officer | Dec 17 '23 | Option Exercise | 0.00 | 10,479 | 0 | 287,412 | Dec 19 05:25 PM | Nuss John | Chief Scientific Officer | Dec 17 '23 | Option Exercise | 0.00 | 34,931 | 0 | 279,746 | Dec 19 05:27 PM | Mohan Raju | CEO and President | Dec 17 '23 | Option Exercise | 0.00 | 116,668 | 0 | 1,629,579 | Dec 19 05:30 PM | NSV Partners III LP | 10% Owner | Oct 09 '23 | Sale | 30.03 | 49,152 | 1,475,858 | 8,439,635 | Oct 11 04:21 PM | Subramaniam Somu | Director | Oct 09 '23 | Sale | 30.03 | 49,152 | 1,475,858 | 8,439,635 | Oct 11 04:18 PM | Mohan Raju | Chief Executive Officer | Oct 05 '23 | Option Exercise | 8.04 | 30,000 | 241,200 | 1,542,911 | Oct 06 07:16 PM | Mohan Raju | Chief Executive Officer | Oct 05 '23 | Sale | 29.11 | 30,000 | 873,231 | 1,512,911 | Oct 06 07:16 PM | Krueger Christopher W | Chief Business Officer | Oct 03 '23 | Option Exercise | 8.04 | 15,000 | 120,600 | 291,548 | Oct 04 07:33 PM | Nuss John | Chief Scientific Officer | Oct 03 '23 | Option Exercise | 3.35 | 10,000 | 33,542 | 254,815 | Oct 04 07:26 PM | Krueger Christopher W | Chief Business Officer | Oct 03 '23 | Sale | 29.98 | 15,000 | 449,699 | 276,548 | Oct 04 07:33 PM | Nuss John | Chief Scientific Officer | Oct 03 '23 | Sale | 29.99 | 10,000 | 299,933 | 244,815 | Oct 04 07:26 PM | Subramaniam Somu | Director | Sep 18 '23 | Sale | 37.81 | 56,665 | 2,142,634 | 8,488,787 | Sep 20 07:19 PM | NSV Partners III LP | 10% Owner | Sep 18 '23 | Sale | 37.81 | 56,665 | 2,142,634 | 8,488,787 | Sep 20 07:16 PM | Mohan Raju | Chief Executive Officer | Sep 05 '23 | Option Exercise | 8.04 | 30,000 | 241,200 | 1,542,911 | Sep 07 04:25 PM | Krueger Christopher W | Chief Business Officer | Sep 05 '23 | Option Exercise | 8.04 | 15,000 | 120,600 | 291,548 | Sep 07 04:28 PM | Nuss John | Chief Scientific Officer | Sep 05 '23 | Option Exercise | 0.20 | 10,000 | 2,000 | 254,815 | Sep 07 04:21 PM | Mohan Raju | Chief Executive Officer | Sep 05 '23 | Sale | 32.61 | 30,000 | 978,343 | 1,512,911 | Sep 07 04:25 PM | Auster Martin | Chief Financial Officer | Sep 05 '23 | Sale | 32.61 | 26,472 | 863,334 | 21,177 | Sep 07 04:31 PM | Krueger Christopher W | Chief Business Officer | Sep 05 '23 | Sale | 32.61 | 15,000 | 489,109 | 276,548 | Sep 07 04:28 PM | Nuss John | Chief Scientific Officer | Sep 05 '23 | Sale | 32.60 | 10,000 | 325,960 | 244,815 | Sep 07 04:21 PM | Sandborn William J. | See Remarks | Aug 31 '23 | Option Exercise | 14.85 | 11,900 | 176,715 | 60,289 | Sep 01 04:45 PM | Sandborn William J. | See Remarks | Aug 31 '23 | Sale | 33.64 | 11,900 | 400,354 | 48,389 | Sep 01 04:45 PM | Sandborn William J. | See Remarks | Aug 08 '23 | Sale | 32.86 | 3,494 | 114,810 | 24,194 | Aug 08 06:57 PM | Mohan Raju | Chief Executive Officer | Aug 07 '23 | Option Exercise | 8.04 | 30,000 | 241,200 | 1,542,911 | Aug 08 06:54 PM | Mohan Raju | Chief Executive Officer | Aug 07 '23 | Sale | 33.52 | 30,000 | 1,005,570 | 1,512,911 | Aug 08 06:54 PM | Krueger Christopher W | Chief Business Officer | Aug 03 '23 | Option Exercise | 8.04 | 15,000 | 120,600 | 291,548 | Aug 04 06:06 PM | Nuss John | Chief Scientific Officer | Aug 03 '23 | Option Exercise | 0.20 | 10,000 | 2,000 | 254,815 | Aug 04 06:08 PM | Krueger Christopher W | Chief Business Officer | Aug 03 '23 | Sale | 35.59 | 15,000 | 533,797 | 276,548 | Aug 04 06:06 PM | Nuss John | Chief Scientific Officer | Aug 03 '23 | Sale | 35.60 | 10,000 | 355,986 | 244,815 | Aug 04 06:08 PM | Sandborn William J. | See Remarks | Jul 31 '23 | Option Exercise | 14.85 | 11,900 | 176,715 | 60,289 | Aug 01 04:21 PM | Sandborn William J. | See Remarks | Jul 31 '23 | Sale | 37.16 | 11,900 | 442,261 | 48,389 | Aug 01 04:21 PM | NSV Partners III LP | 10% Owner | Jul 31 '23 | Sale | 37.59 | 10,803 | 406,035 | 8,545,452 | Aug 01 05:43 PM | Subramaniam Somu | Director | Jul 31 '23 | Sale | 37.59 | 10,803 | 406,035 | 8,545,452 | Aug 01 05:44 PM | Subramaniam Somu | Director | Jul 28 '23 | Sale | 37.53 | 611 | 22,933 | 8,556,255 | Aug 01 05:44 PM | NSV Partners III LP | 10% Owner | Jul 28 '23 | Sale | 37.53 | 611 | 22,933 | 8,556,255 | Aug 01 05:43 PM |
|